Renal-clearable fluorescent probe for early detection of pancreatic cancer in living murine models.

Authors

Minrong Huang, Zhe Zhou, Tong Zhang, Xiaofeng Xia, Wei Chen, Erfei Wang, Feiyi Wang, Jun Ren

Published in

Science advances. Volume 12. Issue 38. Pages eaei0638. Sep 18, 2026. Epub Sep 16, 2026.

Abstract

Pancreatic cancer (PC) is a highly aggressive and lethal malignancy with extremely poor patient survival rates. The lack of biomarkers and deep tissue detection barriers has presented long-standing and unsolved issues, severely hindering the early diagnosis of PC even in living rodent models. Here, we report a renal-clearable leucine aminopeptidase (LAP)-activatable fluorescence probe, overturning the probe's pharmacokinetics from the liver to kidney pathway (90% of the injection dosage). This strategy reduces interference in the liver and enables LAP as a biomarker for PC detection in murine models. After in situ response with LAP in the pancreas, renal-clearable fluorogenic fragments could be efficiently excreted into the urine, thus addressing the depth barriers of PC. Our strategy has resolved the lack of biomarkers and deep tissue detection barriers in early PC detection in murine models, which would greatly expand the bioanalytical toolbox for PC identification, further enabling the efficient screening of PC drugs at the animal level and the exploration of diagnostic methods for PC.

PMID:
42748261
Bibliographic data and abstract were imported from PubMed on 17 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.